Biophytis SA (BPTS): Price and Financial Metrics
GET POWR RATINGS... FREE!
BPTS Stock Price Chart Interactive Chart >
BPTS Price/Volume Stats
| Current price | $1.27 | 52-week high | $13.17 |
| Prev. close | $1.27 | 52-week low | $1.00 |
| Day low | $1.27 | Volume | 1,700 |
| Day high | $1.27 | Avg. volume | 32,610 |
| 50-day MA | $2.00 | Dividend yield | N/A |
| 200-day MA | $6.32 | Market Cap | 17.34M |
Biophytis SA (BPTS) Company Bio
Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Its second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry ager elated macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101). The company was founded in 2006 and is headquartered in Paris, France.
Latest BPTS News From Around the Web
Below are the latest news stories about Biophytis SA that investors may wish to consider to help them evaluate BPTS as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWith a weekend of rest under our belts, we're ready to jump back into investing with the biggest pre-market stock movers for Monday! |
Analysts Are Bullish on Top Healthcare Stocks: BioCardia (BCDA), Biophytis (BPTS)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioCardia (BCDA – Research Report) and Biophytis (BPTS – Research Report) with bullish sentiments. BioCardia (BCDA) In a report released today, Emanuela Branchetti from H.C. Wainwright reiterated a Buy rating on BioCardia, with a price target of $9.00. The company's shares closed last Thursday at $2.09. According to TipRanks.com, Branchetti is ranked #6696 out of 7784 analysts. Currently, the analyst consensus on BioCardia is a Moderate Buy with an average price target of $6.50, which is a 231.6% upside from current levels. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayGood morning, trader! |
BioCardia, Biophytis top healthcare gainers; Kiromic, Mainz Biomed among losersBioCardia BCDA +32%. Biophytis BPTS +17%. Kiromic BioPharma KRBP -17%. Mainz Biomed (MYNZ) -9%. |
Biophytis to treat severe COVID-19 patients with Sarconeos in Brazil under EAPBiophytis (BPTS) soars 21.5% premarket after receiving approval from the ANVISA (Brazilian health authority) for its Expanded Access Program ((EAP)) to treat hospitalized patients |
BPTS Price Returns
| 1-mo | -16.72% |
| 3-mo | N/A |
| 6-mo | -79.19% |
| 1-year | -88.71% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -76.22% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...